Shares of molecular genetics diagnostic company Mainz Biomed B.V. (MYNZ) are down 5 percent on Thursday's trading, thus breaking the stock's upward movement since Wednesday after the company announced that it had acquired exclusive rights to novel mRNA biomarkers.
Mainz Biomed had entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert, the company's easy-to-use detection test for colorectal cancer. Currently at $13.85, the stock has traded between $7.80 and $18.68 during the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.